Nemaura Medical said today it completed development of its 2nd-gen SugarBeat wireless skin-patch continuous glucose monitoring system and aims to launch clinical trials of the device shortly.
The UK-based company’s SugarBeat CGM is designed as a wearable sensor patch which transmits data via bluetooth to provide real time glucose readings on a standalone reader, smart watch or smart phone app, the company said.
Nemaura said it hopes to submit an application for CE Mark approval in the European Union in mid-year, with a launch later in Europe later in the year, dependent upon regulatory approval.
“Adopting a wireless skin-patch format has allowed us to seamlessly integrate our needle-free technology with a diabetic’s own smart device. We have also further refined and enhanced our sensor performance, and are confident that this year’s clinical trials will confirm the efficacy of SugarBeat in helping to improve personal healthcare management for anyone living with diabetes,” Nemaura Medical CEO Dr Faz Chowdhury said in a press release.
Last September, Nemaura said it inked a letter of intent to form a joint venture deal with Chinese Academy of Science subsidiary Shenzen CAS Health Corporation Limited.
Through the deal, the companies aim to establish a joint venture company to distribute its SugarBeat CGM system in China, a manufacturing facility in China and Chinese FDA approval for the device.